Indirect effects of cytomegalovirus (CMV) infections in lung transplant recipients (LTX) have
not previously been described in detail. We compared spirometric results, development of …

Introduction: Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in
solid organ transplant (SOT) patients. Lung transplant recipients are particularly at risk given …

In an attempt to modify the sequelae of cytomegalovirus (CMV) infections after lung
transplantation, 25 allograft recipients were randomized to either ganciclovir 5 mg/kg once a …

BACKGROUND: Cytomegalovirus (CMV) has been associated with morbidity, including
chronic allograft rejection, in transplant recipients. Data from adult centers suggests that …

Cytomegalovirus (CMV) disease has had a significant clinical impact on the heart, heart-
lung and lung transplant recipients in our centre. CMV disease has been so severe with …

Background: Cytomegalovirus (CMV) is the most prevalent opportunistic infection after lung
transplantation. Current strategies do not prevent CMV in most at-risk patients. Objective: To …

Cytomegalovirus (CMV) continues to cause significant morbidity and mortality in lung
transplant recipients. This article presents recommendations based on available evidence …

Purpose Cytomegalovirus (CMV) is among the most important viral pathogens affecting solid
organ recipients. The direct effects of CMV (eg, infection and its sequela; tissue invasive …

The risk factors, clinical associations, and response to treatment of cytomegalovirus (CMV)
pneumonia and infection were studied in 65 recipients of heart-lung transplantation. There …

BACKGROUND: Universal ganciclovir (GCV) prophylaxis is a strategy aimed at reducing
cytomegalovirus (CMV) infection and delaying the development of bronchiolitis obliterans …